MCP1

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
Friday, March 1, 2024
L-DOPA, MCP1, Chemokine, Alzheimer's disease, Phagocytosis, Political moderate, Principal, MDS-UPDRS, Cholesterol, Insulin, Inflammation, Part, ADAS, Plaque, Conference, Placebo-controlled study, Parkinson's disease, Diabetes, Carbidopa/levodopa, Pharmacokinetics, Digestion, Disease, DNA methylation, DNA, Brain, Pharmaceutical industry

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023
VISTA, Patient, MCP1, Biomarker, Pembrolizumab, IL-6, SITC, Immunotherapy, Date, Immunoglobulin G, Clinical trial, NK, DLT, Cytokine release syndrome, Radiation, Annual general meeting, Date-time group, Tumor microenvironment, CXCL10, Safety, CRS, Cancer, Society, Pharmaceutical industry, Vaccine, Kineta

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new positive data from its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.

Key Points: 
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.
  • VISTA blocking immunotherapy KVA12123 has performed remarkably well in demonstrating excellent safety and tolerability in the clinic.
  • KVA12123 achieved a greater than 90% VISTA RO at the 30 mg dose indicating that KVA12123 may be approaching an optimal clinical dose.
  • Additional monotherapy safety and efficacy data and combination therapy clinical data are anticipated in the second quarter of 2024.

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annua

Retrieved on: 
Thursday, November 2, 2023
Patient, MCP1, Aes, IRR, TP53, Bachelor of Medicine, Bachelor of Surgery, AST, Bone marrow, CD47, Azacitidine, Observation, Nausea, Clinical trial, Autoimmune disease, AZA, Safety, Cancer, Cellular, ALT, Combination therapy, Transplant, CD40, AML, Pharmaceutical industry

AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of topline data from the dose escalation portion of its Phase 1 A/B clinical trial of SL-172154 as monotherapy and in combination with azacitidine (AZA) in primarily R/R AML and HR-MDS patients. These data will be featured in a poster presentation at the 65th ASH Annual Meeting, which is being held both virtually and in San Diego, CA from December 9-12, 2023.

Key Points: 
  • “Response rates are historically low for heavily pretreated relapsed/refractory AML and HR-MDS patients.
  • Notably, preliminary data shows anti-leukemic effects detected in previously untreated TP53m-MDS and R/R AML patients.
  • In bone marrow, abundant staining of SL-172154 was observed, along with a dose-dependent increase in phagocytic cells within mature myeloid immune cell compartments.
  • Reduction in leukemic blasts was associated with an increase in mature myeloid and phagocytic cell phenotypes.